Formycon Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Stefan Glombitza

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	7.6yrs
CEO ownership	n/a
Management average tenure	1.9yrs
Board average tenure	9.2yrs

Recent management updates

Recent updates

CEO

Stefan Glombitza (58 yo)

7.6yrs

Tenure

Dr. Stefan Glombitza has been Member of Executive Board at Formycon AG since October 1, 2016 and is Chief Executive Officer from July 01, 2022. Dr. Glombitza served as Chief Operating Officer of Formycon...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stefan Glombitza	CEO & Member of Executive Board	7.6yrs	no data	no data
Friedrich-Wilhelm Steinweg	Co-Founder	no data	no data	no data
Nicolas Combe	Co-Founder	no data	no data	no data
Enno Spillner	CFO & Member of Management Board	1.1yrs	no data	no data
Andreas Seidl	Chief Scientific Officer & Member of Executive Board	1.8yrs	no data	no data
Nicola Mikulcik	Chief Business Officer & Member of Executive Board	1.9yrs	no data	no data
Sabrina Muller	Senior Manager of Corporate Communications & Investor Relations	no data	no data	no data

1.9yrs

Average Tenure

53yo

Average Age

Experienced Management: FYB's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Bernhard Hampl	Member of Advisory Board	10.2yrs	no data	no data
Gerhard Schaefer	Member of Advisory Board	10.5yrs	no data	no data
Olaf Stiller	Chairman of Supervisory Board	14.3yrs	no data	no data
Peter Wendeln	Deputy Chairman of Supervisory Board	14.3yrs	no data	no data
Johannes Buchner	Member of Advisory Board	8.3yrs	no data	no data
Thomas Siklosi	Member of Advisory Board	5.8yrs	no data	no data
Klaus Rohrig	Member of Supervisory Board	3.4yrs	no data	no data
Wolfgang Essler	Member of the Supervisory Board	less than a year	no data	no data

9.2yrs

Average Tenure

Experienced Board: FYB's board of directors are considered experienced (9.2 years average tenure).

Formycon Management

Management criteria checks 1/4

Key information

Recent management updates

Formycon AG Announces Supervisory Board and Executive Changes

Formycon AG Announces Changes to Its Executive Board

Formycon AG, Annual General Meeting, Sep 27, 2021

Recent updates

Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022)

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Price target decreased by 12% to €96.25

New minor risk - Shareholder dilution

Price target decreased by 8.9% to €105

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

New minor risk - Share price stability

Price target decreased by 7.5% to €107

First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022)

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Price target decreased by 8.8% to €115

New minor risk - Share price stability

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

Price target increased to €126

First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021)

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Price target increased to €107

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Full year 2021 earnings: EPS and revenues miss analyst expectations

Formycon AG Announces Changes to Its Executive Board

Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency

Price target increased to €87.00

Price target increased to €75.00

Price target decreased to €70.00

First half 2021 earnings released: €0.92 loss per share (vs €0.14 loss in 1H 2020)

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Full year 2020 earnings released

Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy

Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities

Formycon AG, Annual General Meeting, Sep 27, 2021

New 90-day high: €75.40

Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium

Price target raised to €46.45

New 90-day high: €51.00

Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab)

Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted

New 90-day high: €37.50

New 90-day high: €30.70

First half earnings released

Price target raised to €36.28

New 90-day high - €27.20

Formycon AG to Report Q1, 2020 Results on Jun 22, 2020

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure